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Background. An enormous economic impact can be observed for infected total knee arthroplasties (TKA). The aim of the present
study was to evaluate whether a cost covering treatment of infected TKA is feasible in the German DRG System. Patients and
Methods. Average total treatment costs were evaluated for infected TKA and compared with a matched pair of primary TKA.
Data was generated using the health record and the hospitals’ health information system. Results were evaluated and compared
regarding the total personnel and material costs with respect to the ﬁnancial receipts. Results. A total of 28 patients diagnosed with
an infected TKA were included. A signiﬁcant increase in the average length of stay, use of medical supplies and third party medical
examinations were found for the infected TKA. An average deﬁciency of 6,356C per patient was observed for the infected TKA.
An average proﬁt of 927C per patient was made performing primary TKA. Conclusions. Ac o s t - e ﬀective treatment of infected TKA
was not feasible with the receipts from the German DRG System. An adaption of the receipts has to be evaluated. Moreover, other
measures have to be considered in order to achieve a comprehensive medical yet ﬁnancial reasonable standard in the treatment of
infected TKA and THA.
1.Introduction
1.1. Infected Total Knee Arthroplasties. Total knee arthro-
plasties (TKAs) helped to improve the quality of life of
numerous patients and are considered successful standard
operations in orthopaedic surgery. Annual implant rates add
up to 148.000TKA in Germany alone [1]. Despite advances
in operative techniques and environments, peri-prosthetic
infectionsremainfearedandseverecomplicationsafterTKA.
Deepinfectionaccountsforroughly20%[2]ofTK Ar evision
operations. The reported incidence lies between 0.5 and
1% [3, 4]. A number of risk factors for deep infection
after TKA, such as male sex, rheumatoid arthritis (RA), an
American Society of Anaesthesiologists (ASA) risk score >2,
diabetes mellitus, and morbid obesity, have been identiﬁed
[5].Themostc ommontypeofinfectionsisearlyanddela y ed
TKA infections [4]. Again the most frequently isolated
pathogens are Staphylococcus aureus and coagulase-negative
staphylococci, which account for up to 58% of periprosthetic
TKA infections [4]. Beside the devastating consequences for
thepatient,anenormouseconomicimpactuponthetreating
hospital can be observed.
1.2. Economic Impact of Infected Total Joint Arthroplasties.
Additional average treatment costs of a single infected total
joint prosthesis for both medical and surgical treatment are
estimated to be $30,000 and more [6]. In total, roughly
$1.8 billion additional costs are caused by infected joint
prosthesisandfractureﬁxationdevicesperyearintheUnited
States of America (USA) [6]. The treatment costs of infected
total joint prostheses hence pose a vast burden directly
to the hospital and consequently the corresponding health
care system. Beside the ﬁnancial impact, the enormous psy-
chosocial consequences should of course not be neglected.
Nevertheless treatment of infected TKA becomes more and
more of an economic issue as certain therapy costs are not or
insuﬃciently reﬂected within the German Diagnosis-Related
Groups (G-DRGs) [7].
1.3. DRG System. The DRG System was originally developed
in the 1970s as a patient classiﬁcation system. Patients
were grouped into a limited number of distinct medical
diagnostic categories in order to measure each individual
patient’s consumption of hospital resources[8].Theprimary2 The Scientiﬁc World Journal
purpose of the DRGs was to serve as a basis for quality
assessment, to improve care for patients and for the better
use of limited and expensive medical resources [8, 9]. It
only later evolved to be an eﬃcient measure of cost control
[8]. It is nowadays regarded as a ﬁxed rate reimbursement
system in order to avoid an implausible variation of costs
[10]. Within the system each individual case is assigned
to a corresponding DRG. Complications or comorbidities
may increase the treatment costs and consequently the
reimbursement. The severity of a disease can then be
recognizedandaccountedforwithintheDRGs.TheG-DRGs
were compulsory introduced on January 1, 2004, based
upon the Australian-Reﬁened DRGs. They are designed to
be evolving due to an annual revision and recalculation
with respect to medical cost and performance. Regarding
TKA within the G-DRGs, the annual restructuring led to
a subsequent improvement of the diﬀerentiation criteria
[11, 12]. Furthermore, the introduction of a distinct OPS-
Code for the surgical treatment of severe infections leads to
an improved reﬂection of multiple, complex procedures [11]
that previously had only insuﬃciently been reimbursed.
1.4. Aims and Scope. In the present study, a retrospective
analysis of total treatment costs of infected TKA was per-
formed and compared to a case control group of noninfected
primary TKA. The aim of the present retrospective study
wastoevaluatewhetheracost-coveringtreatmentofinfected
TKA is feasible in the German DRG System. Moreover, the
range of proﬁt respectively loss will be demonstrated.
2. Patientsand Methods
Data was retrospectively analyzed from January 2004 until
December 2007. Initially every infected TKA, treated at
the Department of Orthopaedic Surgery of the University
Hospital Rostock (Orthop¨ adische Universit¨ atsklinik Ros-
tock, OUK), was detected. This included patients who did
receive a primary or revision TKA in our department
as well as patients primarily treated in other hospitals
and transferred to our institution. The case control group
consisted of 21 patients who received a primary TKA in our
department during the analysis period. Case control patients
were selected in a blinded manner. Deﬁnition of the case
control group sample size is based upon calculations of the
Institute of Biostatistics and Informatics in Medicine and
Ageing Research, University of Rostock. Exclusion criteria
of the case control group were metabolic bone diseases,
malign bony tumours, prior radiotherapy, prior ipsilateral
total joint arthroplasty within the last 12 months, or prior
contralateraltotaljointarthroplastywithinthelast6months.
F i r s to fa l l ,i n f e c t e dT K A sw e r ec l a s s i ﬁ e dw i t hr e s p e c tt o
the detected pathogens. Regarding the timing of infection,
infected TKAs were diﬀerentiated in early (<2 months after
implantation), delayed (>2 months until 1 year after implan-
tation), and late infections (>1 year post implantation). Data
was systematically generated using the health record and the
hospitals’ health information system (SAP, Walldorf, Ger-
many). Beside the clinical parameters, DRG relevant costs
and performance variables were evaluated. This included
length of stay, principal and secondary diagnoses, length,
number, and type of operation procedures, number of
hospital stays, length of anaesthesiology, microbiological and
histological exams, laboratory costs, blood products, and
consults. Based upon the federal employee tariﬀ (“Bundes
Angestellten Tarif”, BAT), which was eﬀective during most of
the period of analysis, calculation of medical personnel costs
was performed. Hereby, the oﬃcial standard weekly working
time of 38.5 hours was assumed. Analogous, nonmedical
personnel costs were calculated using the KR V and VI. To
simplify matters, vacation, sickness, age, and marital status
were left unconsidered. According to the Central Controlling
Unit of the University Hospital Rostock (CCU), costs per
anaesthesia minute add up to 7.30C. This includes costs
for medical and nonmedical personnel as well as supply
materials. The average daily costs per patient treated in an
Intensive Care Unit (ICU) are stated to be 1,265C [13]
and were used accordingly. Costs for medical supplies and
pharmaceuticals were calculated after analyses of the health
record, anaesthesiology protocols, surgical reports, and sur-
gical protocols. Analogous, total costs of third party medical
services, namely, microbiological, histological, laboratory,
and radiological examinations were evaluated. A total of
21.23C was charged per microbiological investigation for
performingafungalanalysis,ananalysisinCO2-atmosphere,
an anaerobic and an aerobic analysis, as well as a sensibility
testing in the break-point method. According to the CCU,
a ﬁxed rate of 24.05C per histological examination was
accounted. Furthermore the CCU supplied detailed costs
for individual radiological and laboratory examinations.
Homologous erythrocyte concentrates (ECs) amount to
80.46C, and autologous EC to 77.18C. Calculation of the
exact ﬁnancial reimbursement was performed using the
G-DRG-Online Grouper with respect to the primary and
secondary diagnosis as well as performed procedures, age,
sex, and length of hospitalisation. The base value was set to
be 2,964C.
Statistical evaluation was performed using the Mann-
Whitney test for nonparametric independent samples with
P<0.05 considered to be signiﬁcant.
3. Results
3.1. Patient-Related Results of Infected TKA. During the
period of analysis of this retrospective study, a total of
55 infected TKAs were treated at our institution. Amongst
these patients 22 were initially operated at the OUK, the
remaining 33 transferred from other hospitals. However
patients with a diagnosed TKA infection and only treated
with a single debridement and lavage were not considered
for this study. As a result, a total of 28 patients (8 males;
20 females; average age: 71.7 years) were included. The
average length of hospitalisation was 48.2 days. Treatment
on the ICU of the 28 patients was inevitable on average
for 2.5 days. 10 patients were diagnosed with an early, 5
with a delayed, and ﬁnally 14 with a late TKA infection.
Staphylococcus epidermidis was the most frequently isolatedThe Scientiﬁc World Journal 3
Table 1: Mean absolute und percentage costs of relevant positions in infected TKA.
Cost of implants 5.892,19C 23,39%
Laboratory examinations 268,32C 1,07%
Microbiological examinations 132,65C 0,53%
Histological examinations 111,66C 0,44%
Radiological examinations 247,83C 0,98%
Blood products 502,99C 2,0%
Antibiotics 518,64C 2,05%
Pharmaceuticals 316,5C 1,26%
Medical supplies 4.520,57C 17,94%
Personnel costs OT 714,08C 2,83%
Costs Anaesthesia 2.127,69C 8,45%
Personnel costs general ward 6.760,47C 26,83%
Costs ICU 3.081,61C 12,23%
Total costs 25.194,3C 100%
OT: Operation Theatre; ICU: Intensive Care Unit.
pathogen, followed by Staphylococcus aureus. Histological
signs of infection were detected in 85.7% of the cases (n =
24). A total of 114 operations were performed on the 28
patients, which represents an average of 4.1 operations per
patient. A two-stage TKA reimplantation was performed in
14 cases, a single-stage revision in another four cases. Out
of the 28 patients, 19 received a blood transfusion due to
anaemia. In average, these 19 patients received 7.2 EC. This
again represents an average of 4.5 EC per patient with an
infected TKA. The mean time of anaesthesia was found to
be 95 minutes with a mean operation time of 64 minutes.
3.2. Cost-Speciﬁc Results of Infected TKA. The average total
treatment costs were 25,194C per patient for the infected
TKA (Table 1; Figure 1). 44.2% of the total costs were
allotted to personnel and 55.8% to supply materials. Within
the operation unit, an average of 8,7334C expenses was
observed. Thereby personnel costs were 2,842C and costs for
medical supplies were 5,892C. Calculated cumulative costs
from the ICU were 3,082C, with personnel costs of 1,541C
and 1,541C costs for medical supplies. The average costs on
the general ward were found to be 13,379C, in detail 6,760C
personnel costs and 6,618C charges for medical supplies
(Table 1).
3.3. Patient-Related Results of Case Control Group. The case
control group of primary noninfected TKA consisted of 21
patients (10 males; 11 females; average age: 65.6 years). The
average length of hospitalisation was 13.4 days. Treatment
on the ICU was unnecessary for any patient of the case
control group. As a routine procedure, in 13 patients an
intraoperative microbial swab was taken. Furthermore tissue
was sent for histological examination. Neither histological
signs of infection nor a positive microbial culture was
hereby detected. Out of the 21 patients, 6 received a blood
transfusion due to anaemia. In average, these 6 patients
received 2.2 EC. This again represents an average of 0.6
EC per patient of the case control group. The mean time
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Figure 1: Mean, standard deviation, minimum, and maximum
values of the various positions for infected TKA in Euro.
of anaesthesia was found to be 112 minutes with a mean
operation time of 82 minutes.
3.4. Cost-Speciﬁc Results of Case Control Group. The average
total treatment costs were 6,889C per patient for the case
control group (Table 2).43.4%ofthetotalcostswereallotted
to personnel and 56.6% to supply materials. Within the
operation unit, an average charge of 3,266C was observed.
Thereby personnel costs accumulated to 1,091C and costs
for medical supplies to 2,174C. Total cumulative costs
on the general ward were found to be 3,623C,i nd e t a i l
1,896Cpersonnelcostsand1,728Ccostsformedicalsupplies
(Table 2).4 The Scientiﬁc World Journal
Table 2: Mean absolute and percentage costs of relevant positions case control group (noninfected primary TKA).
Cost of implants 2.174,48C 31,57%
Laboratory examinations 88,13C 1,28%
Microbiological examinations 15,16C 0,22%
Histological examinations 4,58C 0,07%
Radiological examinations 169,34C 2,46%
Blood products 42,15C 0,61%
Antibiotics 5,66C 0,08%
Pharmaceuticals 96,82C 1,41%
Medical supplies 1.305,86C 18,96%
Personnel costs OT 274,17C 3,98%
Costs Anaesthesia 816,90C 11,86%
Personnel costs general ward 1.895,60C 27,52%
Total costs 6.888,85C 100%
OT: Operation Theatre.
Table 3: Cost analysis of infected TKA and the case control group with reimbursements from the G-DRGs in Euro (C).
Group Number of patients Mean cost per patient Mean reimbursement (G-DRGs) Mean proﬁt/loss Cost coverage
Infected TKA 28 25,194C 18,838C −6,356C 74.77%
Case control group 21 6,889C 7,816C +927C 111.86%
3.5. Cost Analysis. Regarding the 28 patients with the
diagnosis of an infected TKA, a mean loss of 6,356C between
reimbursements from the G-DRGs and total calculated costs
was observed per patient. This results in a cost coverage of
only 74.77%. On the other hand, a mean proﬁt of 927C can
be achieved performing primary TKA. The cost coverage is
calculated to be 111.86% with an average reimbursement of
7,816C and total costs of 6,889C (Table 3).
4. Discussion
In the present study, a cost analysis was performed regarding
28 patients diagnosed with an infected TKA, treated at the
OUK. The corresponding costs were compared to a case
control group of 21 patients with a noninfected primary
TKA. We were able to demonstrate that a proﬁt of 927C can
be achieved performing primary TKA, where on the other
hand a mean loss of 6,356C was observed treating infected
TKA (Table 3). Breaking down the matters of expense,
obvious diﬀerences between length of hospitalisation and
cumulative operation time can be found for infected and
noninfected TKA. This again is represented by the con-
siderable increase of total costs. The prolonged length of
hospitalisation and cumulative operation time account for
the increase of personnel costs within the operation unit and
on the general ward. Furthermore, the use of antibiotics as
wellasotherpharmaceuticalsanderythrocyteconcentratesis
signiﬁcantlyincreasedforpatientswithaninfectedTKA(P<
0.05).Thesamecouldbedemonstratedforcostsarisingfrom
third party medical services and medical supplies. Finally,
treatmentcostsfromtheICUwereonlyobservedforpatients
with infected TKA (Tables 1 and 2).
In literature implant costs for primary TKA have been
found to be $10,989 in the USA in the late 1980s and
accounted for roughly 40% of the total charges [14]. In
t h ep r e s e n ts t u d y ,w ew e r es t i l la b l et od e m o n s t r a t es i m i l a r
charges regarding the cost analysis of primary, noninfected
T K An o w a d a y si nG e r m a n y .H o w e v e rt o t a lb i l l e ds u r g i c a l
fee by the surgeon alone accounted for 20% of the total
charges [14] whereas in the present study the majority of
costs are due to the sum of charges of cumulative operation
time, implants and pharmaceuticals. This might partly be
due to the diﬀerent accounting procedures in the USA and
Germany. Recently, the hospital economics of primary TKA
have been analyzed [15]. From 1991 to 2009 a loss per
case of US $2,172 was converted into a proﬁt of US $2,086
per primary TKA. According to the authors, reduction of
hospital length of stay and reduction of knee implant costs
were the major drivers of the hospital expense reduction.
In 1991, the average duration of hospital stay was 9.0 days
whereas,in2008,itwasreducedtoanaverageofonly3.7days
[15]. According to our results, a proﬁt may also be achieved
performing primary TKA in the G-DRG System. However
our own results show a considerably higher duration of
hospitalstayof13days,whatexplainsthelowerproﬁtmargin
which might therefore be increased by adapting to interna-
tionalstandardsofhospitalisation.In2008,hospitalexpenses
in primary TKA was $11,002 in the USA [15]. We were able
todemonstratesimilarexpensesof6,889Cbetween2004and
2007. As opposed to our results, costs for pharmaceuticals,
laboratory exams, and operation time were found to be
higher in the USA. However, regarding the percentage they
seem to be more or less consistent with our results from
a German University Hospital [15]. Comparable expenses
of US $7,331 per primary TKA can furthermore be found
in Canada (charges converted into US dollars) [16]. The
authors furthermore demonstrated that $1,667 have to be
spent for every 10-point increase of the WOMAC (WesternThe Scientiﬁc World Journal 5
OntarioMcMasterArthritisQuestionnaire)[17]forapatient
undergoing primary TKA compared to $2,602 per 10-point
increase for patients undergoing aseptic TKA revision [16].
No such calculation has however been performed for the
treatment of infected TKA. Nevertheless surgical treatment
of an infected TKA requires three to four times the resources
of hospital and surgeon compared with a primary TKA and
approximately twice the resources of a nonseptic revision
TKA [18]. A net loss of approximately $30,000 (22,545C)
was hereby observed per Medicare patient [18]. Yet almost
two decades of age and from the USA, these results are still
consistent with our present ﬁndings. It has been stated that
the reimbursement rates will not even cover hospital costs
for TKA revision surgery with substantially higher costs for
patients with deep joint infections. It is even suggested that
TKA revision due to deep infection is one of the highest
resource consumption procedures in orthopaedic surgery
[19]. This again is supported by the recent ﬁndings of a
signiﬁcantincreaseofmeantreatmentcostsforinfectedTKA
compared to noninfected revision TKA [20]. A signiﬁcant
increased length of stay and mean costs for examinations is
demonstrated for the treatment-infected TKA [20]. These
results again coincide with our ﬁndings. However in our
study we furthermore show an increase in implant costs and
the ﬁnancial impact of the necessity due to intensive care
treatment.
In summary, there is a consensus in the present literature
that a cost covering treatment of infected TKA is not
feasible in most healthcare systems. A proﬁt however may
beachievedperformingprimaryTKA.Neverthelessthereisa
lackofdetailedcostcoveragecalculationsregardingthetreat-
ment of infected TKA. Our results therefore complement
the present literature by the point of view from the G-DRG
System.
Next to the general limitations of a retrospective study,
there are further obvious limitations. The present paper only
focuses on direct medical costs whereas other, nonmedical
costs such as loss of production, salary, and social security
taxes were not included. The socioeconomic impact of
infected TKA is therefore left unconsidered. Furthermore,
the data was only generated at one institution. Despite
the fact that this oﬀers the opportunity of a detailed and
patient-speciﬁc analysis of clinical data and charges, only a
limited conclusion may be drawn upon the general German
healthcare system. Further studies are anticipated in order
to compare our results with the results from other German
hospitals. Moreover, prices were evaluated in 2011 and
no adjustments of inﬂation have been taken into account.
Another limitation is of course that only infected TKAs were
analysed. A comparison between noninfected and infected
TKA revision is hence not possible in the present study.
We furthermore abdicated on the diﬀerentiation between
infected primary and revision TKA, as, apart from a higher
rateofinfectionafterrevisionTKA,nosigniﬁcantdiﬀerences
in the general treatment and hence charges are expected.
Finally comparability of our results with results from other
publications is hindered due to the shortened length of stay
internationally.
5. Conclusion
During the observed period, a cost-covering treatment of
infected total knee arthroplasties was not feasible with the
reimbursements from the German DRG System. The average
loss per patient was 6.356C.T h em a i nr e a s o n sw e r ef o u n dt o
be the signiﬁcant increase of personnel and supply material
costs in comparison to the noninfected primary total knee
arthroplasties (P<0.05). Besides, the necessary treatment
procedures are not suﬃciently reﬂected and rewarded within
the German DRG System. An adaption of the reimburse-
ments has hence to be evaluated. However, other measures
have to be considered in order to achieve cost-eﬀectiveness.
Multicentre cost analysis and extensive measures of quality
control are anticipated, in order to achieve a comprehensive
medical yet ﬁnancial reasonable standard in the treatment of
infected total knee arthroplasties.
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